Adam M.  Veness net worth and biography

Adam Veness Biography and Net Worth

Mr. Veness is Senior Vice President, General Counsel, and Secretary. Since joining Acceleron in 2014, Mr. Veness has held various positions of increasing responsibility leading to his appointment as General Counsel. Mr. Veness established Acceleron’s securities compliance and capital markets internal capabilities as well as the commercial compliance function. He also served as Acceleron’s Compliance Officer until he became General Counsel in 2019.

Prior to joining Acceleron, Mr. Veness was a corporate and securities attorney at the Boston offices of the law firm Mintz Levin. At Mintz Levin, he represented and counseled public and private companies in the biopharmaceutical, technology, and healthcare industries in securities and capital markets transactions, securities compliance, venture capital financings, executive compensation, and corporate governance. Earlier in his career, Mr. Veness was an attorney for a boutique litigation firm representing companies and individuals in a variety of matters, including employment and general civil litigation.

Mr. Veness received a B.A. in political science and philosophy from Tulane University and a J.D. from Boston University School of Law.

What is Adam M. Veness' net worth?

The estimated net worth of Adam M. Veness is at least $3.26 million as of January 5th, 2021. Mr. Veness owns 18,219 shares of Acceleron Pharma stock worth more than $3,256,646 as of March 29th. This net worth estimate does not reflect any other assets that Mr. Veness may own. Learn More about Adam M. Veness' net worth.

How do I contact Adam M. Veness?

The corporate mailing address for Mr. Veness and other Acceleron Pharma executives is 128 SYDNEY STREET, CAMBRIDGE MA, 02139. Acceleron Pharma can also be reached via phone at (617) 649-9200 and via email at [email protected]. Learn More on Adam M. Veness' contact information.

Has Adam M. Veness been buying or selling shares of Acceleron Pharma?

Adam M. Veness has not been actively trading shares of Acceleron Pharma over the course of the past ninety days. Most recently, Adam M. Veness sold 6,650 shares of the business's stock in a transaction on Tuesday, September 21st. The shares were sold at an average price of $150.05, for a transaction totalling $997,832.50. Learn More on Adam M. Veness' trading history.

Who are Acceleron Pharma's active insiders?

Acceleron Pharma's insider roster includes Habib Dable (CEO), Sujay Kango (EVP), Terrence Kearney (Director), Thomas McCourt (Director), Kevin McLaughlin (CFO), Adam Veness (SVP), and Joseph Zakrzewski (Director). Learn More on Acceleron Pharma's active insiders.

Adam M. Veness Insider Trading History at Acceleron Pharma

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/21/2021Sell6,650$150.05$997,832.50View SEC Filing Icon  
9/8/2021Sell6$130.00$780.00View SEC Filing Icon  
1/5/2021Sell2,056$122.56$251,983.3618,219View SEC Filing Icon  
9/8/2020Sell2,000$89.50$179,000.0020,090View SEC Filing Icon  
4/8/2020Sell6,000$85.58$513,480.0027,161View SEC Filing Icon  
1/2/2020Sell434$52.83$22,928.2215,667View SEC Filing Icon  
9/10/2019Sell824$45.20$37,244.8016,124View SEC Filing Icon  
8/9/2019Sell3,268$45.00$147,060.0016,925View SEC Filing Icon  
7/16/2019Sell538$40.71$21,901.9820,193View SEC Filing Icon  
See Full Table

Adam M. Veness Buying and Selling Activity at Acceleron Pharma

This chart shows Adam M Veness's buying and selling at Acceleron Pharma by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Acceleron Pharma Company Overview

Acceleron Pharma logo
Acceleron Pharma, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its product candidates include Luspatercept, designed to patients with chronic anemia associated within a wide range of blood diseases; ACE-083, designed for the treatment of focal muscle disorders; and Sotatercept, designed to treat pulmonary arterial hypertension. The company was founded by John L. Knopf and Thomas P. Maniatis in June 2003 and is headquartered in Cambridge, MA.
Read More

Today's Range

Now: $178.75
Low: $178.75
High: $178.75

50 Day Range

MA: $176.25
Low: $172.08
High: $179.68

2 Week Range

Now: $178.75
Low: $108.82
High: $189.99

Volume

N/A

Average Volume

572,759 shs

Market Capitalization

$10.93 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.13